Abstract | OBJECTIVE: METHODS: RESULTS: CONCLUSION: Long-term therapy with anti-TNF-α is promising in ameliorating body mass decrease in patients with active RA. Plasma levels of ghrelin, GIP and leptin may play significant roles in maintaining energy homeostasis in the anti-inflammatory responses during RA remission.
|
Authors | Chih-Yen Chen, Chang-Youh Tsai, Pui-Ching Lee, Shou-Dong Lee |
Journal | Current pharmaceutical design
(Curr Pharm Des)
Vol. 19
Issue 10
Pg. 1956-64
( 2013)
ISSN: 1873-4286 [Electronic] United Arab Emirates |
PMID | 23305268
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antirheumatic Agents
- Gastrointestinal Hormones
- Immunoglobulin G
- Leptin
- Receptors, Tumor Necrosis Factor
- Etanercept
|
Topics |
- Adult
- Antirheumatic Agents
(pharmacology, therapeutic use)
- Appetite
(drug effects)
- Arthritis, Rheumatoid
(complications, drug therapy)
- Body Composition
- Body Mass Index
- Cachexia
(etiology, prevention & control)
- Etanercept
- Female
- Gastrointestinal Hormones
(physiology)
- Humans
- Immunoglobulin G
(pharmacology, therapeutic use)
- Leptin
(physiology)
- Male
- Middle Aged
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Weight Gain
(drug effects)
|